Irreversible Proteasome Inhibitor Carfilzomib 868540-17-4

Payment Type: T/T
Incoterm: CIF
Min. Order: 1 Kilogram
Delivery Time: 15 Days

Basic Info

Model No.: 868540-17-4

Additional Info

Packaging: AS REQUIRED

Productivity: KGS


Transportation: Air

Place of Origin: CHINA


Certificate: ISO

Product Description

Carfilzomib cas number is 868540-17-4,which is an intravenously administered tetrapeptide epoxy ketone backbone proteasome inhibitor that selectively and irreversibly binds to the N-terminus of the threonine active site of the 20S proteasome, proteolytically Core particle 26S proteasome. Carfilzomib has antiproliferative and apoptotic activities against solid tumors as well as hematological tumor cells in vitro. In animal studies, carfilzomib inhibits proteasome activity in blood and tissues and delays tumor growth in multiple myeloma, hematology, and solid tumor models. It was approved by the US FDA on July 20, 2012. For patients with relapsed multiple myeloma who have received both therapies including bortezomib and an immunomodulator.
Although carfilzomib cas 868540-17-4 has a good anti-tumor effect, its water solubility is poor, and its stability is not good. The lyophilized preparation is an ideal dosage form. The currently available carfilzomib formulation contains 60 mg of carfilzomib. 3000mg sulfobutyl beta-cyclodextrin sodium and 57.7mg citric acid and an appropriate amount of sodium hydroxide, although the cyclodextrin inclusion compound improves the solubility of the drug to a certain extent, but its drug loading is still less than 2%, And the use of a larger amount of cyclodextrin, will enter the human blood circulation system will increase the burden on the kidney, while cyclodextrin can interact with the cell membrane of the blood vessel wall, causing cell damage, long-term use may cause venous fistula and phlebitis, there are safety risks And dexamethasone is given to prevent the infusion reaction before each dose. In addition, the drug is very unstable in aqueous media solutions and is stable for up to 4 hours at room temperature, which is also a challenge in practical clinical applications.
In summary, the currently marketed carfilzomib injection has a good effect in the treatment of multiple myeloma, but it also brings a lot of inconvenience and safety problems to clinical application.

Carfilzomib CAS 868540-17-4, also known as PR-171 A potent and irreversible proteasome inhibitor. Synthetic analog of the microbial product epoxomcin. Compared to bortezomib it displays equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome. In cell culture it is more cytotoxic than bortezomib and hematologic tumor cells exhibit greater sensitivity than solid tumor cells. Treatment of cells with  Carfilzomib CAS 868540-17-4 results in the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis. Effective against multiple myeloma. Active in vivo.

Thera. Category: Anti cancer

Cas No.868540-17-4

Synonym: CarfilzoMib salt;CarfilzoMib/PR 171;PR-171 (CarfilzoMib)


Molecular Formula:C40H57N5O7

Molecular Weight:719.90988


PackingExport worthy packing

lMaterial Safety Data SheetAvailable on request 

Usage: Carfilzomib  868540-17-4, A potent and irreversible proteasome inhibitor.

Active Pharmaceutical Ingredients> Cas 90098-04-7,Rebamipide Named In Mucosta With GMP Standard
Active Pharmaceutical Ingredients> Functional Dyspepsia Treatment Acotiamide Hydrochloride Trihydrate CAS 773092-05-0
Active Pharmaceutical Ingredients> Acotiamide Hydrochloride For Gastric Motility Improvement CAS 185104-11-4
Contract Manufacturing> ASCORBYL GLUCOSIDE Used for Comesitc Additive CAS 129499-78-1
Pharmaceutical Intermediates> Anti-Ulcerative> 2-Aminothiazole-4-ethylformate For Making Acotiamide Cas 5398-36-7
Pharmaceutical Intermediates> Anti-Ulcerative> Acotiamide INT CAS NUMBER 185105-98-0
Pharmaceutical Intermediates> Anti-Cardiovascular> Azilsartan Used for Hypertension Treatment CAS 147403-03-0
Pharmaceutical Intermediates> Anti-Diabetes> Sitagliptin Phosphate Monohydrate Treated for Type 2 diabetes CAS Number 654671-77-9
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 132210-24-3, 2-Amino-3-(1,2-dihydro-2-oxo-quinoline-4-yl)Propanoic acid Hydrochloride For Rebamipide
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 1068-90-2 White Crystalline Powder Diethyl Acetamidomalonate For Rebamipide(DAAM)
Active Pharmaceutical Ingredients> 6027-23-2, Hordenine HCL Powder
Pharmaceutical Intermediates> Anti-Ulcerative> Cas 4876-10-2,4-Bromomethyl-2(1H)-quinolinone (BMQ) For Rebamipide/ Mucosta
Pharmaceutical Intermediates> Anti-Respiratory> CAS 2338-18-3, 2-Aminoindan hydrochloride For Making Indacaterol
Pharmaceutical Intermediates> Anti-Respiratory> CAS 312753-53-0/ 5,6-Diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride Used for Indacaterol
Pharmaceutical Intermediates> Anti-Respiratory> 312753-53-0, Indacaterol Intermediate
Pharmaceutical Intermediates> Anti-Respiratory> 100331-89-3, Indacaterol Intermediate

© 2019 CHINA WAY. All Rights Reserved.  Taizhou Volsen Chemical Co., Ltd.,  Inc.   All rights reserved. site map.  sitemap.html